Nuzzo, Silvia (2018) Selection of aptamers targeting a hypoxia marker: Carbonic Anhydrase-IX (CA-IX). [Tesi di dottorato]

[img]
Anteprima
Testo
Silvia_Nuzzo_XXX_ciclo_Doctorate_in_Molecular_Medicine_and_Medical_Biotechnology_short_version.pdf

Download (932kB) | Anteprima
[img]
Anteprima
Testo
Silvia_Nuzzo_XXX_ciclo_Doctorate_in_Molecular_Medicine_and_Medical_Biotechnology_long_version_.pdf

Download (2MB) | Anteprima
[error in script] [error in script]
Tipologia del documento: Tesi di dottorato
Lingua: English
Titolo: Selection of aptamers targeting a hypoxia marker: Carbonic Anhydrase-IX (CA-IX)
Autori:
AutoreEmail
Nuzzo, Silvianuzzo.silvia@gmail.com
Data: 2018
Numero di pagine: 94
Istituzione: Università degli Studi di Napoli Federico II
Dipartimento: dep14
Dottorato: phd054
Ciclo di dottorato: 30
Coordinatore del Corso di dottorato:
nomeemail
Avvedimento, Vittorio Enricovittorioenrico.avvedimento@unina.it
Tutor:
nomeemail
de Franciscis, Vittorio[non definito]
Data: 2018
Numero di pagine: 94
Parole chiave: aptamers, hypoxia
Settori scientifico-disciplinari del MIUR: Area 06 - Scienze mediche > MED/04 - Patologia generale
Depositato il: 27 Dic 2017 23:52
Ultima modifica: 25 Lug 2020 01:00
URI: http://www.fedoa.unina.it/id/eprint/12248

Abstract

Aptamers are selected by an in vitro combinatorial chemistry approach, named Systematic Evolution of Ligands by Exponential enrichment (SELEX), and they are able to bind with high affinity and specificity virtually any given molecule. Compared to monoclonal antibodies, they have a small size that results in their rapid tumour penetration; they are not immunogenic and could be easily modified to increase their in vivo stability. Thus, in this study we describe the selection of RNA-based aptamers directed against an hypoxic biomarker. Firstly, we performed two different cell-based SELEX protocols that allowed the specific enrichment for the target. Furthermore, we characterized and improved the two best sequences selected, named S-47s1 and S-51s1, that we are still studying to handle a final product usable for diagnostic and therapeutic purposes.

Downloads

Downloads per month over past year

Actions (login required)

Modifica documento Modifica documento